Researchers have delved into the intricate heterogeneity of glioblastoma, a notoriously aggressive brain tumor, using advanced single-cell RNA sequencing and innovative zebrafish avatars. Their findings spotlighted the LGALS1 gene’s role in immunosuppression and suggested potential therapeutic avenues for personalized GBM treatment.
No Benefit for PD-1 Inhibitors in Certain Gastroesophageal Cancers, FDA Panel Says
By way of two resoundingly consistent votes, members of an FDA advisory committee agreed that PD-1 inhibitors do not have a favorable risk/benefit profile for
September 28, 2024